Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-52

OMG!
This is more than interesting, and it is becoming very hard to keep up with the developments of IMU.
Another collaboration and this time using the partner's treatment as the delivery agent and IMU as the killer.
This is almost the opposite MO to onCARlytics. Is there anything that the CF33 suite can't deliver?

I noted several things here, as other have also noted regarding the difficulties of 'hitting' pancreatic cancer. Not just a 'tricky'
cancer, the 'mother of all tricky', as explained in the release.
I also note that this 'combo' will widen the therapeutic window, thus allowing a larger, but safer dose ... and one that hits the target ...
like nothing before it. Are we now looking at a real treatment for pancreatic cancer? I don't know, but it seems we will have some
idea in 4 MONTHS! This is crazy.
They were also the 2020 Fierce Pharma awardee. They are HOT!
Now IMU is just a littler hotter too.

I didn't see this one coming. So the roadshow is looking extra interesting now.